Page 4 - Eric Elenko News Today

Tekla Capital Management LLC lifted its holdings in Karuna Therapeutics, Inc. (NASDAQ:KRTX – Get Rating) by 126.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 53,452 shares of the company’s stock after buying an additional 29,836 shares during the period. […]

Castleark Management LLC grew its stake in Karuna Therapeutics, Inc. (NASDAQ:KRTX – Get Rating) by 121.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 24,936 shares of the company’s stock after purchasing an additional 13,690 shares during the quarter. Castleark Management LLC […]

Hamilton Lane Advisors LLC reduced its stake in Karuna Therapeutics, Inc. (NASDAQ:KRTX – Get Rating) by 17.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 64,090 shares of the company’s stock after selling 13,196 shares during the period. Karuna Therapeutics accounts […]

Karuna Therapeutics (NASDAQ:KRTX – Get Rating) had its target price increased by Mizuho from $270.00 to $274.00 in a research note released on Monday morning, The Fly reports. KRTX has been the topic of several other reports. Wells Fargo & Company lowered their price objective on Karuna Therapeutics from $262.00 to $257.00 and set an […]

Arizona State Retirement System grew its position in Karuna Therapeutics, Inc. (NASDAQ:KRTX – Get Rating) by 4.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,549 shares of the company’s stock after acquiring an additional 294 shares during the quarter. Arizona […]

Karuna Therapeutics (NASDAQ:KRTX – Get Rating) had its price target lifted by Mizuho from $270.00 to $274.00 in a research note published on Monday morning, The Fly reports. A number of other equities analysts also recently commented on KRTX. Wedbush restated an outperform rating on shares of Karuna Therapeutics in a report on Tuesday, March […]

Karuna Therapeutics (NASDAQ:KRTX – Get Rating) had its price objective lifted by investment analysts at Mizuho from $270.00 to $274.00 in a research report issued to clients and investors on Monday, The Fly reports. Mizuho’s target price points to a potential upside of 25.68% from the company’s current price. A number of other research firms […]

Karuna Therapeutics (NASDAQ:KRTX – Get Rating) announced its quarterly earnings results on Thursday. The company reported ($2.80) EPS for the quarter, topping analysts’ consensus estimates of ($2.86) by $0.06, Briefing.com reports. Karuna Therapeutics had a negative return on equity of 34.88% and a negative net margin of 2,795.96%. The company had revenue of $0.65 million […]

Karuna Therapeutics (NASDAQ:KRTX – Get Rating) is scheduled to be releasing its earnings data before the market opens on Thursday, May 4th. Analysts expect Karuna Therapeutics to post earnings of ($2.86) per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link. Karuna Therapeutics […]

Karuna Therapeutics, Inc. (NASDAQ:KRTX – Get Rating) has been assigned an average rating of “Moderate Buy” from the sixteen ratings firms that are covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and twelve have issued a buy recommendation on the company. The average twelve-month target price […]